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Background: Studies based on laboratory data about thyroid stimulating hormone (TSH) and free thyroxine (FT4)
reference interval (RI) show conflicting results regarding the importance of using specific values by age groups with
advancing age. Retrospective laboratory data or non-specific criteria in the selection of subjects to be studied may
be factors leading to no clear conclusions. The aim of this study is to test the hypothesis that TSH and FT4 have
specific RI for subjects over 60 to 80 years.
Methods: We evaluated prospectively 1200 subjects of both sexes stratified by age groups, initially submitted to a
questionnaire to do the first selection to exclude those with factors that could interfere in TSH or FT4 levels. Then,
we excluded those subjects with goiter or other abnormalities on physical examination, positive thyroid peroxidase
antibodies (TPOAb), thyroglobulin antibodies (TGAb), and other laboratory abnormalities.
Results: TSH increased with age in the whole group. There was no statistical difference in the analysis of these
independent subgroups: 20–49 versus 50–59 years old (p > 0.05), and 60–69 versus 70–79 years old (p > 0.05).
Consequently, we achieved different TSH RI for the three major age groups, 20 to 59 years old: 0.4 - 4.3 mU/L, 60 to
79 years old: 0.4 - 5.8 mU/L and 80 years or more: 0.4 - 6.7 mU/L. Conversely, FT4 progressively decreases = significantly
with age, but the independent comparison test between the sub-groups showed that after age 60 the same RI was
obtained (0.7 - 1.7 ng/dL) although the minimum value was smaller than that defined by manufacturer. In the comparison
between TSH data obtained by this study and those defined by the manufacturer (without segmentation by age) 6.5% of
subjects between 60 and 79 years and 12.5% with 80 years or more would have a misdiagnosis of elevated TSH.
Conclusions: TSH normal reference range increases with age, justifying the use of different RI in subjects 60 years old and
over, while FT4 decreases with age. Using specific-age RI, a significant percentage of elderly will not be misdiagnosed as
having subclinical hipothyroidism.Introduction
In recent decades there has been increased life expect-
ancy of the population and, consequently, of the aging
process. Persons older than age 60 comprise 20 per cent
of the world population in the more developed regions,
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stated.The oldest old, persons aged 80 years or older, is the
fastest growing segment of the older population and by
2050 the number of this group is projected to be five
times as large as at present [1].
Several aspects of the aging process affect the endo-
crine system and stimulate the use of screening pro-
grams for the detection of hormonal changes and drug
interventions with hormone replacement therapies to
provide better quality of life for the elderly. Evaluation of
thyroid function in normal elderly is difficult, since the
prevalence of non-thyroid disease and the use of medi-
cations that interfere with thyroid function is greaterLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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meaning of functional changes observed in the elderly
are relatively common [2].
Data interpretation of thyroid function in the elderly
has been changing over the past decades. In a study con-
ducted in 1995 in a non-selected population, the authors
considered that subjects of any age with some degree of
TSH elevation had some grade of thyroid gland failure
[3]. However, in 2002, the NHANES III study revisited
this parameter data in a population excluding those with
evidence of thyroid disease and, in this more uniform
population, TSH still showed a progressive increase with
age [4].
The International Federation of Clinical Chemistry and
Laboratory Medicine (IFCC) Committee developed the
theory of reference values for the “Reference Intervals and
Decision Limits (CRIDL)” [5]. In 1995 the Clinical and
Laboratory Standards Institute (CLSI) first published with
IFCC the joint guideline “Defining, Establishing, and
Verifying Reference Intervals in the Clinical Laboratory”,
reviewed in 2008 [6]. This document recommends appli-
cation of prospective questionnaires and, if necessary,
physical evaluation, of candidate subjects to be part of a
control group. It also discourages the indirect approach in
which database results are used to establish ranges, retro-
actively identifying acceptable reference populations. This
has been a challenge since then, and many clinical labora-
tories do not have these procedures performed in accord-
ance with the recommendations, due to the fact that they
require time, additional costs, knowledge, and efforts to
further clarify physicians and patients.
Recent studies have shown conflicting results regard-
ing the decision to use reference intervals (RI) of TSH
suitable for the elderly or not [7,8]. On studies with re-
view of medical records, it is difficult to use strict inclu-
sion and exclusion criteria in the selection of subjects
representing a control group. Several bias may occur
due to registration errors, and omission of information
that were not actively taken from the patient. The conse-
quent inclusion of a significant number of subjects with
potential thyroid or general disease or use of interfering
medications as belonging to the control group that may
alter the final data obtained is a real possibility. Thus,
the theme is still far from being exhausted, and this
topic is relevant regarding the issue of not to hyper diag-
nose subclinical hypothyroidism in the elderly who actu-
ally could have higher TSH, but at appropriate levels for
their age.
Likewise, as FT4 is the test of choice for the confirm-
ation of thyroid disease, it is also relevant to assess
whether there is a need for RI specific for subjects above
60 years and 80 years or older.
The aim of this study was to test the hypothesis that it is
necessary to use specific RI for TSH and FT4 for subjectsover 60 years old, and over 80 years old, compare the
values with those of young subjects, and analyze the im-
pact of using specific TSH RI for these age groups in the
screening of thyroid dysfunction.
Materials and methods
Between March and December 2012, 1200 subjects of
both sexes were evaluated prospectively distributed as
follows: 120 males and 120 females in each of the fol-
lowing age ranges: 20–49, 50–59, 60–69, 70–79 and
above 80 years, who attended a clinical laboratory to
collect routine tests for which function evaluation and/
or thyroid autoimmunity had not been requested. They
were invited to participate in order to arrive at the la-
boratory on pre-determined weekdays, according to
availability of the researchers. A questionnaire was ap-
plied by one of the researchers, through direct inter-
views with participating candidates, which consisted of:
1) Identification data, address and phone number of the
participants, as well as the name and telephone number
of their physician for communication in case of abnor-
mal results; characterization of their color or race ac-
cording to themselves; if they consider themselves as
healthy individuals; personal or familial thyroid disease
in the present or past; current medications (among these,
medications containing iodine in the last six months),
smoking, hospitalization due to illness or accident in the
last six months (and what the disease was), and pregnancy
(for females who had not had menopause). Subjects were
from the metropolitan area of Rio de Janeiro, belonging to
middle and upper social class, as declared income, 77%
white, 18% mulatto and 5% black. Subjects with negative
thyroid peroxidase antibodies (TPOAb) and thyroglobu-
lin antibodies (TGAb), normal lipid profile, ultrasensitive
C-reactive protein level (CRP), blood count, renal func-
tion, and absence of goiter on palpation were in the inclu-
sion criteria. The measurement of urinary iodine was not
done since the salt iodization in Brazil is determined by
federal law [9] and the authors have shown in previous
study that the intake iodine in the Rio de Janeiro popu-
lation is sufficient [10]. In addition, the National Health
Surveillance Agency (ANVISA), which is the regulatory
agency under the Ministry of Health, conducted a review
of salt iodization in the samples used in Rio de Janeiro in
the year before beginning of the study confirming that it
was appropriate [11].
Exclusion criteria included past or present history of
thyroid disease, previous thyroid surgery, family history
of thyroid disease, TSH <0.1 mU/L or > 10.0 mU/L, as
these results indicate a high probability of thyroid dys-
function [12], palpable goiter, smoking habit, use of
medicines known as possible analytical or physiological
interference on measurement of TSH or FT4 in the past
three months (medicines and contrasts containing iodine
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tions and other drugs that may interfere with TSH and/or
FT4 measurements [13-24], antidepressants, hospitalization
in the past six months and pregnant females. As changes in
thyroid morphology are significantly higher among the
elderly, we assessed whether this was a factor in generating
different results in the selection of subjects for the study. A
thyroid ultrasonography (US) was performed on 687 sub-
jects with exclusion of 24.1% who presented some thyroid
change. More than 120 subjects still remained in each
group. Comparing TSH and FT4 values between subjects
who had normal US and those who did not perform US,
there was no statistically significant difference (data not
shown). Therefore, as this exam was not essential in the se-
lection of subjects as controls, all of the initially selected
subjects could be enrolled in the study, except those who
were initially excluded and had been replaced by the same
number of other subjects of the same age and sex in order
of maintaining the initial number to be studied.
List of medications and other drugs that may interfere
with TSH and/or FT4 measurements
2-3-dimercatopropanol, 2-4-dinitrophenol,
5-fluorouracil, 5-hydroxytryptophan
Acetazolamide, acetylsalicylic acid, alpha adrenergic
blockers, aminoglutethimide, aminotriazole,
amiodarone, androgens and other anabolic steroids,
anphenona, anphetamines, antipyrine
Benserazide, beta adrenergic blockers, bexarotene,
bromine, brompheniramine
Cadmium, carbamazepine, chromate, chromium
picolinate, cimetidine, clofibrate, clomiphene,
clomipramine, cobalt, complex anions, corticosteroids,
cytostatics
Danazol, diphenylhydantoin, dinitrophenol,
dobutamine, domperidone, dopamine and its agonists,
other dopaminergic agents
Erythrosine, estrogens, ethionamide
Fenclofenac, fenoldopam, flunarizine, fluor, furosemide,
fusaric acid
Growth hormone (GH), GH-Releasing hormone
Halofenate, heroin, heparin
Interleukins, iopanoic acid, other radiological contrasts,
and other iodine-containing substances and drugs
(potassium iodide and others), insulin-like Growth
Factor-1, interferon
Ketoconazole
L-asparaginase, L-dopa inhibitors, levothyroxine,
lithium, lovastatin,
Mefenamic acid, melatonin, metformin, methadone,
methimazole, metoclopramide, mitotane
Nevirapine, niacin, nicotinic acid, nifedipine, NSAIDs,
nitrateO, p’-DDD, orphenadrine, opioids, oxcarbazepine
Para-aminobenzoic acid, perchlorate, perphenazine,
phenidone, phenylbutazone, phenobarbital, pimozide,
prazozin, primidone, propylthiouracil, pyridoxine
Quetiapine
Raloxifen, resorcinol, rifampicin, ritonavir, rubidium
Salsalate, serotonergics antagonists, somatostatin and
its analogues, spironolactone, St. John’s Wort,
stavudine, sulfonamides, sulfonylureas, sulpiride,
steroids hormones
Tamoxifen, thiocyanate, thyroid hormones and their
analogs, troleandomycin, tyrosine kinase inhibitors
Valproic acid
Drugs are listed in alphabetical order and not in pos-
sible importance as interfering in TSH or thyroid hor-
mone values.
The study was approved by the Research Ethics
Committee of the Hospital Clementino Fraga Filho,
Universidade Federal do Rio de Janeiro (HUCFF/UFRJ)
and individuals agreed to participate by signing the in-
formed consent form.
Collection of data and collection of samples
Serum was collected in the morning, in same species
standard sampling tubes with separator gel. The mea-
surements were done on the same day in primary tubes,
after blood centrifugation at 3200 RPM for 15 min.
Biochemical data
Serum TSH, FT4, TPOAb and TGAb were measured by
electrochemiluminescence immunoassays on the Roche
Modular Analytics® E170 (Roche Diagnostics Australia
Pty Ltd, Castle Hill, NSW, Australia).
Serum TSH concentrations were measured by an immu-
nometric method, with an intra-assay percentage coeffi-
cient of variation (% CV) of 3.0% at concentrations of
0.040 ± 0.001 mU/L, 2.7% at 0.092 ± 0.002 mU/L and
1.1% at 9.4 ± 0.1 mU/L. The reference interval provided
by the manufacturer is 0.3- 4.2 mU/L. Serum FT4, TPOAb
and TGAb concentrations were measured by competitive
assays. For FT4, the % CV was 1.4% at FT4 concentrations
of 0.7 ± 0.01 ng/dL, 1.8% at 1.3 ± 0.02 and 2.0% at 2.7 ±
0.1 ng/dL. The reference interval provided by the manu-
facturer is 0.9 -1.7 ng/dL. For TPOAb the intra-assay %
CV is 6.3% at TPO concentrations of 21.3 ± 1.34 IU/mL,
5.1% at 51.2 ± 2.6 IU/mL and 2.7% at 473 ± 12.7 IU/mL.
According to the manufacturer, individuals without thy-
roid disease score lower than 34 IU/mL. For TGAb the
intra-assay % CV is 4.9% at TG concentrations of 47.2 ±
2.3 IU/mL, 1.3% at 588 ± 7.4, and 1.3 at 3289 ± 42.0 IU/
mL TGAb concentrations. According to the manufac-
turer, individuals without thyroid disease score lower
than <115 IU/mL.
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Data were analyzed using the program GraphPad Prism®,
version 6.0 (GraphPad Software, Inc, California). In order
to assess the Normal distribution of both data series (TSH
and FT4) Kolmogorov-Smirnov tests were performed.
Logarithmic 10 was used for analysis. TSH and FT4 were
calculated for each subgroup and gender from 20 to
49 years, then, by 10-year age range until 80 years; all
those aged older than 80 were grouped together. Descrip-
tive analysis of serum TSH was reported as medians and
25% and 75% percentiles because it is not normally dis-
tributed. Two tailed Mann–Whitney test and Kruskal-
Wallis test were used to compare the nonparametric TSH
distributions in different subpopulations. Evaluation be-
tween two subgroups was made by independent test of
Dunn multiple comparisons. Means and standard devia-
tions were calculated for FT4, since it has showed a nor-
mal distribution. For comparing FT4 between all groups,
two-way ANOVA tests were used when more than two
data series were analyzed, and Student test in the case of
two data series.
Outlying observations were calculated using the test
proposed by Dixon. In all cases, the level of significance
used was 0.05 [25]. For the RI, for both hormones 2.5%
and 97.5% were taken. We used the method of Harris
and Boyd [26] to decide whether it was necessary to sep-
arate the reference values for gender. According to this
method, to calculate the statistical significance of the dif-
ference between the means of groups standard normal
deviation (z), if the value z is less than 3 means there is
no need to reference values separated by gender.
To calculate correlations between TSH and FT4 levels
in all age groups, TSH data were transformed into loga-
rithmic 10. With normal distribution the two-tailedTable 1 Statistical data of TSH measurements
20-49 50-59
Mean age females (years old) 34.3 54.1
Mean age males (years old) 35.2 53.9
Median TSH in females 1.5
Median TSH in males 1.5
z values and p values between gender z = −1.45 p = 0.30 z = −0.60
Minimum TSH 0.3 0.4
Maximum TSH 5.8 5.9
25% TSH percentile 1.1 1.2
75% TSH percentile 2.2 2.6
Lower 95% CI 1.6 1.8
Upper 95% CI 1.9 2.1
Median TSH assumed 1.5
Minimum and maximum TSH RI assumed 0.4 – 4.3
RI: reference interval SD: standard deviation TSH in mU/L.Pearson test was used; it was considered statistically sig-
nificant if a p-value was less than 0.05. Pearson test was
also used to analyze, individually, correlations between
TSH and age and FT4 and age.
Results
TSH data
The reference group was comprised of 50% females and
50% males. The mean age by gender in each age sub-
groups are in Table 1. TSH data analysis by age or gen-
der exhibited a non-Gaussian distribution. In each age
group, there was no significant difference in serum TSH
median between males and females (Table 1). Therefore,
considering these factors, all individuals were eligible in
each group for the establishment of reference intervals.
Statistical parameters of TSH measurements are listed in
Figure 1 and in Table 1. Analysis of median TSH as a
whole group showed that there was a significant increase
of this hormone with age (p < 0.001), but the analysis of
independent subgroups, 20–49 years old versus 50–
59 years old (p > 0.05), and 60–69 years old versus 70–
79 years old (p > 0.05), showed no statistically significant
difference. These data confirm that different RI for three
major age groups should be used: 20 to 59 years, 60–
79 years and 80 years or more. RI calculated for each
sub-group are shown in Table 1.
FT4 data
FT4 exhibited a Gaussian distribution. Data of FT4 mea-
surements are shown in Figure 2, and statistical parame-
ters are listed in Table 2. Analysis of FT4 mean ± standard
deviation (SD) shows that there is a significant reduction
of the hormone with age as a whole group (p < 0.0001).














0.4 – 5.8 0.4 – 6.7
Figure 1 Graph-distribution of TSH among different age
groups. The transverse line marks median values.
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groups showed that there was no statistically significant
difference between those over 60 years old. Reference in-
tervals calculated for FT4 are shown in Table 2.
Regarding the correlation between TSH and FT4, a high
level of significance was observed in all age sub-groups,
independently analyzed (p < 0.0001), 20–49 years old:
Pearson r = −0.4641, 95% confidence interval (CI) = −
0.4961 to −0.2926, R squared = 0.1652; 50–59 years old:
Pearson r = −0.3862, 95% CI = −0.4881 to −0.2739, R
squared = 0.1492; 60–69 years old: Pearson r = −0.4653,
95% CI = −0.5583 to −0.3607, R squared = 0.2165; 70–
79 years old: Pearson r = −0.4946, 95% CI = −0.5839 to −
0.3934, R squared = 0.2446; 80 years old and over: Pearson
r = −0.3951, 95% confidence interval = −0.4961 to −0.2835,
R squared = 0.1561.
In order to assess whether the RI obtained in this
study had clinical impact regarding the use of RI defined
by the manufacturer in screening for thyroid disease, we
compare the percentage of subjects who had TSH belowFigure 2 Graph-distribution of FT4 among different age
groups. The transverse line marks median values.or above the RI defined by age range obtained from this
study with the values without segmentation by age. The
results are showed in Table 3.
Discussion
Usually, for the interpretation of a laboratory test, clin-
ical laboratories use RI provided by the manufacturer of
lab kits. The result of a patient’s test is then compared
to this RI in order to diagnose whether it is normal or
not. TSH concentration is the most sensitive test to reli-
ably detect thyroid function abnormalities and is used as
the screening test for studying thyroid function because
of the inverse log-linear relationship between circulating
TSH and FT4 concentrations [27,28].
This study, conducted prospectively with a reference
population, showed that TSH increases progressively
and significantly with age. The value of z less than 3.0 in
all age groups indicates that the same RI should be
adopted for both genders. On the other hand, FT4 tends
to decrease with age. In the age groups above 60 years,
FT4 values are equal between males and females. In sub-
jects younger than 60, the value of z pointed that FT4
is lower in males than in females. A study of Kratzsch
et al. also reports lower FT4 in males than in females
[29]. However, as in our study, z result (3.0249) is very
close to the cutoff point we consider that in the clinical
routine, it is appropriate to use the same RI to both gen-
ders, the same way as in older subjects.
The lower TSH limit defined in this study of 0.4 mU/L
is the same for all age groups over 60 years old, and does
not differ from the lower limit of younger people. This
value is in accordance with previous study using third
generation immunometric TSH methodology, that refers
to the lower TSH reference limit as approximately 0.3 to
0.4 mU/L, irrespective of the population studied or the
method used [30]. The value found in this study, very
slightly higher than that reported by the manufacturer,
has no impact on an eventual reclassification of how
many people have low TSH, as the difference between
one and other is under 2%.
Association between TSH and age is highly significant.
The median is 1.5 mU/L in people under 60 years old,
increases to 1.7 mU/L from 60 to 79 years old, and to
2.0 mU/L for those aged 80 or more. Upper TSH limit
increases from 4.3 mU/L under 60 years old, to 5.8 mU/L
in the range of 60 to 79 years old and to 6.7 mU/L in
those very old subjects, over 80. So, although the manu-
facturer’s TSH kit is suitable for subjects less than
60 years of age, the same is not true for those 60 years
or more, in which the limits are significantly higher.
Within the age ranges of 60–79 years and 80 years or
over, a significant percentage of subjects are reclassified
as having not elevated TSH if age-specific RI is adopted.
The same does not occur in young subjects. According
Table 2 Statistical data of FT4 measurements
Age groups
20-49 50-59 60-69 70-79 ≥80
Mean FT4 ± SD in females 1.2 ± 0.03 1.2 ± 0.24 1.1 ± 0.22 1.2 ± 0.24 1.1 ± 0.24
Mean FT4 ± SD in males 1.3 ± 0.02 1.2 ± 0.25 1.1 ± 0.23 1.1 ± 0.22 1.1 ± 0.23










Minimum level FT4 0.7 0.7 0.7 0.7 0.7
Maximum level FT4 1.9 1.9 1.8 1.8 1.8
Lower FT4 95% CI 1.2 1.2 1.1 1.1 1.1
Upper FT4 95% CI 1.3 1.2 1.2 1.2 1.2
Mean FT4 ± SD assumed for both genders 1.2 ± 0.3 1.2 ± 0.3 1.1 ± 0.2 1.1 ± 0.2 1.1 ± 0.2
Minimum and maximum FT4 RI assumed for both genders 0.7 – 1.9 0.7 – 1.7
RI: reference interval SD: standard deviation FT4 in ng/dL.
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of subjects between 60 and 70 years and 12.5% of those
with 80 years or more have less misdiagnosis of elevated
TSH, leading to 19% reclassification from hypothyroidism
to normal, using these criteria. With regard to the effects
of age on serum TSH levels, other epidemiological studies
indicate that the population’s mean TSH levels increase
with age [4,31,32]. The NHANES III was the best designed
in selecting a control population, and data obtained were
similar to the current study, indicating that increase in
TSH is probably a physiological event for the elderly
[33,34] or that this increase may be due to the presence of
TSH isoforms with low bioactivity [35]. In each scenario
one can avoid excessive diagnosis of subclinical hypo-
thyroidism in the elderly adopting specific RI. And, to clar-
ify the second hypothesis, the answer would be the
development and clinical use of technologies to quantify
only isoforms with normal TSH bioactivity.
Failure to find these differences in RI between the
young and the elderly reported in other studies may be
due to retrospective studies based, or selection choosing
populations to be reference for which strict selection cri-
teria were not applied through specific questionnaires
and appropriate physical examination to exclude factors
such as thyroid dysfunction in the subject or in theTable 3 Comparison of data of TSH (mU/L) obtained regardin
by age), with the results of this study that redefined RI speci





With segmentation by age
in this study
Differe
< 60 0.4% 0.8% + 0.4%
60-79 0.4% 2.1% + 1.7%
≥ 80 0.4% 0.8% + 0.4%
*Refers to percentage of subjects detected with TSH levels out of reference interval
this study and RI was segmented by age.family, interfering medications, other illnesses, recent
hospitalizations, smoking habits and goiter.
Like TSH, FT4 has the same minimum reference value
for all age groups. This value of 0.7 ng/dL however, is
lower in relation to that defined by the manufacturer
(0.9 ng/dL) in all groups. In relation to the maximum
reference value, the level of 1.7 ng/dL is suitable to be
used for subjects 60 years old and over. However, al-
though this is not the scope of this study, the results ob-
tained by us suggest that a higher reference superior
value (1.9 ng/dL) should be used for young individuals.
Previous study demonstrated that FT4 remained rela-
tively unchanged with age [36]. These data can be difficult
to interpret because evaluation of thyroid function in the
elderly is often complicated by the increased prevalence of
chronic illness and the use of medication. In the present
study, subjects with one or more of these factors were ex-
cluded. There is evidence that a low activity of thyroid
hormone might be beneficial in the elderly. Low levels of
FT4 have been associated with a better survival in elderly
subjects [8,33,37,38]. On the other hand, even thyroid hor-
mone levels within the normal range might be associated
with thyroid hormone-related endpoints. As an example,
in euthyroid subjects, especially the elderly, FT4, regard-
less of TSH levels is associated with atrial fibrillation, andg RI defined by the manufacturer (without segmentation
fic for age range
Results of TSH upper RI (mU/L)
nce* Defined by the
manufacturer
With segmentation by age
in this study
Difference*
1.7% 1.5% - 0.2%
9.2% 2.7% - 6.5%
14.5% 2.0% - 12.5%
(RI) established by the manufacturer versus those where TSH was obtained in
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these lower levels of thyroid hormone could possibly serve
as an adaptive mechanism to prevent catabolism in the
elderly [41].
We consider relevant the data obtained in this age-
related prospective study, once it is very important to dis-
tinguish between normal and mildly elevated serum TSH
concentrations in elderly subjects. Elevations of TSH in
young individuals even light and without decreasing FT4
characterize subclinical hypothyroidism or minimal thy-
roid dysfunction and are related to comorbidities such as
dyslipidemia, adverse obstetric events, impact on cogni-
tion, quality of life, cardiovascular events, and evolution to
clinical hypothyroidism [42]. These effects have no corres-
pondence in the elderly, since there is no evidence of these
effects in this age group [43,44]. There is a consensus
that subjects with TSH concentrations above 10.0 mU/L
should be treated. However, according to Garber et al., in
the Clinical Practice Guidelines for Hypothyroidism, very
mild TSH elevations in older individuals, under this level,
may not reflect subclinical thyroid dysfunction, but rather
be a normal manifestation of aging. While the normal
TSH reference may need to be narrowed range for some
subpopulations [27,45], the normal RI may widen with
aging [24]. This confirms that not all patients who have
mild TSH elevations are hypothyroid and therefore would
not require thyroid hormone therapy. These data are
also relevant for the monitoring of subjects with hypo-
thyroidism, since the target for TSH in levothyroxine
treated subjects should be higher in elderly people. Pitfalls
in the interpretation of TSH were carefully excluded in
this study. Abnormal levels are observed in various non-
thyroidal diseases and other conditions, but the effect of
possible changes secondary to thyroid diseases were pre-
ventable excluding subjects who had used medication con-
taining iodine during the previous 6 months, had had
hospitalization, smokers, as well as those not using any
medication that may alter minimally TSH or thyroid
hormones.
Concluding, this data shows that prevalence of sub-
clinical hypothyroidism is overestimated in the elderly,
in almost 20% of subjects, unless age-specific RI is used.
This might improve diagnostic accuracy and reduce the
need of confirmatory unnecessary tests.
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